Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science

Ilan Irony, MD

Janssen Pharmaceutical Companies of Johnson and Johnson, United States

Senior Director, Global Regulatory Leader

Jennifer Sugg

AstraZeneca, United States

Principal Statistician

David G. Orloff, MD

Medpace, Inc., United States

Executive Director, Regulatory Affairs

Robert J. Temple, MD

FDA, United States

Senior Advisor for Clinical Science, OCD and Immediate Office, OND, CDER

Börje C. Darpö, MD, PhD

Clario, Sweden

Chief Scientific Officer, Cardiac Safety